Background and Aims: The study aims to determine the sensitive and specific of circulating tumor cell (CTC) in the diagnosis of solitary pulmonary nodules (SPN).
nosis of NSCLC, especially in the GGO is higher than the sub-solid nodule (SSN) and solid nodule (P < 0.05).Compared with the existing clinical biomarkers such as neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), cyfra211, and squamous cell carcinoma antigen (SCC Ag), the method showed the higher diagnostic efficiency (area under the curve, 0.641; 95% confidence interval, 0.508-0.760). CTC, NSE, CEA, CA125, cyfra211 and SCC Ag was the highest diagnostic efficiency (area under the curve, 0.75; 95% confidence interval, 0.622-0.878).
Conclusion:
Our results demonstrated that CTCs were feasible diagnostic biomarkers in patients with SPN, especially in grilled glass nodules (GGO). Furthermore, CTC combined with the other tumor marker show the highest diagnostic efficiency. Background and Aims: Introduction Osteosarcoma often metastasizes to the lung, and the 5-year survival rate of osteosarcoma with pulmonary metastasis is less than 40%. Therefore treatment is considered to be an important factor affecting prognosis.
Methods:
We report a case of long-term survival with carrying out local treatment mainly on multiple surgical resection for osteosarcoma multiple lung metastasis.
Results: Case When she was 28 years old, she received a widespread resection of right tibial osteosarcoma, and adjuvant chemotherapy after surgery was performed. 4 years later, she underwent resection for bilateral multiple lung metastasis (55 right, 61 left). After that, she underwent multiple surgeries for bilateral lung metastasis. When she was 38, 41, 44, 45, 50 years old, she received removal of 69, 55, 3, 1, 5 metastasis tumor. We resected a total of about 250 tumours. Furthermore, radiofrequency ablation (RFA) and radiotherapy and percutaneous ethanol injection therapy (PEIT) were performed. When she was 51 years old, the remaining another lesion gradually increased, therefore we considered surgery. However, a new lesion was found in the right ventricle by preoperative PET / CT. Although chemotherapy and surgical treatment were considered, she hoped for palliative treatment. She died after 23 years after the removal of the primary lesion.
Conclusion:
We experienced a case of long-term survival by multidisciplinary therapy centred on multiple surgical resections. Results: In all, 117 patients were enrolled. Sixty patients were stage IIA, 25 patients were stage IIB, and 82 patients were stage IIIA. The PFS of stage IIA patients who received platinum+vinorelbine has a trend to be longer (29.6 months vs 14.9 months, P = 0.129). The PFS of stage IIB and IIIA is not reached. Patients received combination chemotherapy seems to have a longer PFS, although not statistically significant (15.6 months vs 8.8 months, P = 0.657). Finally, patients who received platinum + vinorelbine is not significantly longer than those received platinum+other chemotherapy (17.9 months vs 12.0 months, P = 0.24). According to different N stage, the PFS for N0 is not reached. The PFS of N1 disease was 17.7 months, and of N2 disease was11.6 months.
Combination chemotherapy is still a preferred treatment choice after surgery before more efficient treatment strategy is found. Background and Aims: Immunotherapy in non-small cell lung cancer (NSCLC) patients with diagnosis of autoimmune disease is thought to be high risk of developing immune symptoms. However, little is known about immunotherapy in NSCLC patients positive for antinuclear antibody (ANA), which indicates some type of autoimmune condition. We aimed to clarify the relationship between ANA titer and outcome of immunotherapy in NSCLC.
Methods:
We retrospectively reviewed thirty-one patients who were diagnosed with NSCLC and treated with PD-1 inhibitor, either Nivolumab or Pembrolizumab at our hospital from January 2016 to April 2018. We categorized them into three groups by the ANA test (indirect immunofluorescence assay); positive for ANA group (≥80), borderline for ANA group ( =40), negative for ANA group (<40). We investigated the difference of treatment effect and adverse event (AE) among three groups.
Results: According to ANA titer, four patients were categorized as positive for ANA group, ten patients as borderline for ANA group, and seventeen patients as negative for ANA group. Positive for ANA group had high response rates (RR 75%) and good progression-free survival (median PFS 10.65 months), and other two groups had lower RR and worse PFS than positive for ANA group. In addition, all patients of positive for ANA group experienced AEs, while less than 25% patients experienced AEs in other two groups. Two patients in positive for ANA group had to interrupt their treatments because of AEs, in particular interstitial lung diseases which led to respiratory failure and required systemic
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